These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17998685)

  • 1. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.
    Vivek RS; Baludavid M; Mohanram R; ; ; ; ; ;
    J Cancer Res Ther; 2006; 2(3):90-6. PubMed ID: 17998685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
    Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
    J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.
    Gupta T; Agarwal JP; Ghosh-Laskar S; Parikh PM; D'Cruz AK; Dinshaw KA
    Head Neck Oncol; 2009 Jun; 1():17. PubMed ID: 19527507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216).
    Adelstein DJ; Moon J; Hanna E; Giri PG; Mills GM; Wolf GT; Urba SG
    Head Neck; 2010 Feb; 32(2):221-8. PubMed ID: 19557750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
    Gupta P; Dhull AK; Kaushal V
    J Cancer Res Ther; 2020; 16(3):478-484. PubMed ID: 32719254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas.
    Medina JA; Rueda A; de Pasos AS; Contreras J; Cobo M; Moreno P; Benavides M; Villanueva A; Alba E
    Radiother Oncol; 2006 Apr; 79(1):34-8. PubMed ID: 16626826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensification regimen 2 for advanced head and neck squamous cell carcinomas.
    Grecula JC; Schuller DE; Rhoades CA; Au JL; Nag S; Bauer CJ; Agrawal A; Martinez-Monge R; Johnson A; Young D; Gahbauer RA
    Arch Otolaryngol Head Neck Surg; 1999 Dec; 125(12):1313-8. PubMed ID: 10604408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients.
    Koness RJ; Glicksman A; Liu L; Coachman N; Landman C; Slotman G; Wanebo HJ
    Am J Surg; 1997 Nov; 174(5):532-5. PubMed ID: 9374231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
    Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
    Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
    Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.
    Dimri K; Pandey AK; Trehan R; Rai B; Kumar A
    Asian Pac J Cancer Prev; 2013; 14(11):6883-8. PubMed ID: 24377620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
    Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
    J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of the treatment outcome of moderately accelerated radiation fractionation (with concurrent chemotherapy in daily dosing) to conventional chemo-radiotherapy in locally advanced head and neck cancers: Supportive in a resource constrained environment.
    Arora C; Sharma N; Kapoor A; Pandya TN
    Indian J Cancer; 2024 Apr; 61(2):262-272. PubMed ID: 38090961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma.
    Kutter J; Ozsahin M; Monnier P; Stupp R
    Eur Arch Otorhinolaryngol; 2005 Jan; 262(1):1-7. PubMed ID: 15004704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
    Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
    Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
    Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS
    J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.